TRIB Valuation

Trinity Biotech PLC

Add to Watchlist

Advanced Chart

0.720

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

TRIB Relative Valuation

TRIB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TRIB is overvalued; if below, it's undervalued.

Historical Valuation

Trinity Biotech PLC (TRIB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.29 is considered Undervalued compared with the five-year average of 1.32. The fair price of Trinity Biotech PLC (TRIB) is between 1.19 to 2.11 according to relative valuation methord. Compared to the current price of 0.72 USD , Trinity Biotech PLC is Undervalued By 39.41%.

Relative Value

Fair Zone

1.19-2.11

Current Price：0.72

39.41%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-0.37

P/B

Median3y

-1.76

Median5y

-39.59

-33.88

FCF Yield

Median3y

-37.68

Median5y

-10.20

Competitors Valuation Multiple

The average P/S ratio for TRIB's competitors is 1.20, providing a benchmark for relative valuation. Trinity Biotech PLC Corp (TRIB) exhibits a P/S ratio of 0.29, which is -76.17% above the industry average. Given its robust revenue growth of 3.24%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap